In this podcast, Prof. Josep Llovet and Prof. Stephen L. Chan describe patients who can benefit from monotherapy, and they  share current guidance on implementation of dosing strategies for the management of toxicity in clinical practice. They discuss first line monotherapy with TKI (lenvatinib or sorafenib) for patients who are not suitable for the treatment with atezo-bev combination (around 20% of the patients), which is the current standard of care. They summarize the HCC patients who are not ideal for this I/O combination, such as HCC patients with liver transplantation, high bleeding risk, impaired liver function or severe autoimmune disease.

The experts discuss which patients can benefit from TKI and provide a summary of efficacy and safety data from several pivotal clinical studies (including SHARP, REFLECT, IMbrave150), as well as real-world data. Dosing strategies for VEGFR-TKIs and management of AEs are discussed, as well as guideline recommendations. Finally, the experts anticipate key developments over the next few years, focusing on the new immunotherapy combinations that could become new standard of care.

This HCC CONNECT podcast is also available on
Castos, Spotify, Apple Podcasts, and Google Podcasts.

HCC CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer, AstraZeneca and from Eisai Europe Limited.